Tue, September 11, 2012
Mon, September 10, 2012
Sun, September 9, 2012
Fri, September 7, 2012
Thu, September 6, 2012
Wed, September 5, 2012
Tue, September 4, 2012
Mon, September 3, 2012
Sun, September 2, 2012
Sat, September 1, 2012
Fri, August 31, 2012
Thu, August 30, 2012
Wed, August 29, 2012
Tue, August 28, 2012

The Briscoe Law Firm and Powers Taylor, LLP Investigate Sale of Medicis Pharmaceutical to Valeant Pharmaceuticals International


//health-fitness.news-articles.net/content/2012/ .. al-to-valeant-pharmaceuticals-international.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


DALLAS--([ ])--Former United States Securities and Exchange Commission attorney [ Willie Briscoe ] and the securities litigation firm of [ Powers Taylor, LLP ] are investigating the sale of [ Medicis Pharmaceutical Corporation ] (aMedicisa) (NYSE: MRX) to Valeant Pharmaceuticals International, Inc. for shareholders. Under the proposed transaction, Medicis shareholders will only receive $44.00 in cash for each share of Medicis stock owned, well below at least one analystas estimate of $45.00 per share.

"Due to the lack of a significant premium to the shareholders and other factors, we believe that the transaction may undervalue Medicis stock. Our lawsuit will seek to obtain the highest share price for all shareholders"

If you are an affected investor, and you want to learn more about the lawsuit or join the action, contact Patrick Powers at Powers Taylor, LLP, toll free (877) 728-9607, via email at [ patrick@powerstaylor.com ], or Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 706-9314, or via email at [ WBriscoe@TheBriscoeLawFirm.com ]. There is no cost or fee to you.

The transaction is valued at approximately $2.6 billion and is expected to close in the first half of 2013.

The investigation centers on whether Medicis shareholders are receiving adequate compensation for their shares in the buyout, whether the transaction undervalues Medicis stock, and whether Medicisas board attempted to obtain the highest share price for all shareholders prior to agreeing to the deal. According to Yahoo! Finance, at least one analyst has estimated that the true inherent value of Medicis stock may be as high as $45.00 per share. aDue to the lack of a significant premium to the shareholders and other factors, we believe that the transaction may undervalue Medicis stock. Our lawsuit will seek to obtain the highest share price for all shareholders,a said shareholder rights attorney Willie Briscoe.

[ The Briscoe Law Firm, PLLC ] is a full service business litigation and shareholder rights advocacy firm with more than 20 years of experience in complex litigation and transactional matters.

[ Powers Taylor, LLP ] is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions.


Publication Contributing Sources